Latest Interviews
Showing 1–1 of 1 interview transcripts.
Clear all filters- Goldman Sachs14 min
From “The Way Forward" Conference: Esther Krofah, Executive Director, FasterCures
Faster Cures currently monitors over 200 SARS-CoV-2 therapeutic candidates and 163 vaccine prospects, with the majority of treatments in Phase 2 or 3 testing and key programs like Moderna's mRNA vaccine and the Oxford/AstraZeneca project advancing rapidly. While early data supports Remdesivir and convalescent plasma as partial solutions, experts anticipate effective cures will likely emerge from combination therapies and require Emergency Use Authorizations between fall 2020 and early 2021. Vaccine availability for frontline workers is targeted for late 2020, though the accelerated 12-to-18-month timeline relies on aggressive manufacturing scaling and successful clinical data readouts expected by autumn.